{
    "nctId": "NCT05296317",
    "briefTitle": "Evaluation and Modeling of the Effect of G-CSF on the Evolution of Polynuclear Neutrophils During Dense Dose Epirubicin-Cyclophosphamide Regeneration",
    "officialTitle": "Evaluation and Modeling of the Effect of G-CSF on the Evolution of Polynuclear Neutrophils During Dense Dose Epirubicin-Cyclophosphamide Regeneration",
    "overallStatus": "RECRUITING",
    "conditions": "Localized Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "SUPPORTIVE_CARE",
    "enrollmentCount": 100,
    "primaryOutcomeMeasure": "Variation of Neutrophils concentration in patient treated with G-CSF or peg-G-CSF",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Women\n* Patient over 18 years old\n* Patient with histologically documented, non-metastatic breast cancer who must receive dense dose Epirubicin-Cyclophosphamide (EC) type treatment as part of neoadjuvant or adjuvant treatment\n* Patient to receive granulocyte growth factors (G-CSF or peg-G-CSF) as a preventive measure from the first cycle\n* Neutrophils \\> 1,500 /mm3; platelets \\> 100,000 /mm3\n* Written informed consent, dated and signed\n* For patients of childbearing age, effective means of contraception during treatment and up to 3 months after stopping treatment\n\nExclusion Criteria:\n\n* Patient with a contraindication to treatment with anthracyclines\n* Patient already undergoing treatment with EC dense dose\n* Patient with a contraindication to treatment with G-CSF such as hypersensitivity to the active ingredient or to one of the excipients\n* Pregnant or breastfeeding women\n* Patient under guardianship or curatorship or subject to a protection regime for adults\n* Patient not affiliated to a social security scheme (beneficiary or beneficiary)",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}